Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease.

ABSTRACT: Diabetes is the leading cause of chronic kidney disease (CKD) and kidney failure worldwide. CKD frequently coexists with heart failure and atherosclerotic cardiovascular disease in the broader context of cardio-kidney-metabolic syndrome. Diabetes and CKD are associated with increased risk of all-cause and cardiovascular death as well as decreased quality of life. The role of metabolic and hemodynamic abnormalities has long been recognized as an important contributor to the pathogenesis and progression of CKD in diabetes, while a more recent and growing body of evidence supports activation of both systemic and local inflammation as important contributors. Current guidelines recommend therapies targeting pathomechanisms of CKD in addition to management of traditional risk factors such as hyp

SUBMITTER: Neumiller JJ 

PROVIDER: S-EPMC10783256 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature